PTCT - Ptc Therapeutics News

Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Ptc Therapeutics (PTCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

PTC Therapeutics: Q3 Earnings Snapshot AP - Thu Oct 26, 3:26PM CDT

PTC Therapeutics: Q3 Earnings Snapshot

Why PTC Therapeutics Soared 15% Higher Today Motley Fool - Thu Oct 19, 6:02PM CDT

The company scored a $1 billion upfront payment for expanding a commercial partnership.

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PR Newswire - Mon Oct 16, 3:30PM CDT

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire - Fri Sep 29, 4:28PM CDT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...

PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce PR Newswire - Thu Sep 28, 3:30PM CDT

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire - Thu Sep 21, 2:29PM CDT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...

CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization PR Newswire - Fri Sep 15, 5:00AM CDT

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community PR Newswire - Thu Sep 7, 7:00AM CDT

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy. Through the...

PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire - Wed Aug 30, 7:00AM CDT

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Citi 2023...

PTC Therapeutics: Q2 Earnings Snapshot AP - Thu Aug 3, 3:14PM CDT

PTC Therapeutics: Q2 Earnings Snapshot

MAIN MENU

POPULAR

quotes

charts

technicals

options

company

analysts

financials

Barchart Exclusives

Want to use this as
your default charts setting?

Switch the Market flag

Want Streaming Chart Updates?

Need More Chart Options?

Free Barchart Webinar